ELEVAI LABS INC. - COMMON STOCK

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

22 11 2024 18:23:15 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

22 11 2024 17:00:04 提供 Nasdaq GlobeNewswire

CORRECTION - Elevai Labs Inc.

14 11 2024 14:35:59 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

14 11 2024 09:08:00 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

04 11 2024 17:45:39 提供 Nasdaq GlobeNewswire

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

22 10 2024 09:54:26 提供 Nasdaq GlobeNewswire

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

21 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

04 10 2024 17:08:26 提供 Nasdaq GlobeNewswire

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

03 10 2024 15:45:00 提供 Nasdaq GlobeNewswire

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

03 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device

02 10 2024 08:30:00 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

23 9 2024 08:45:00 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

10 9 2024 07:30:24 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

03 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

28 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

26 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

19 8 2024 09:00:00 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

14 8 2024 09:05:44 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

30 7 2024 09:00:26 提供 Nasdaq GlobeNewswire

Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line

28 6 2024 09:00:00 提供 Nasdaq GlobeNewswire